Etodolac/cyclodextrin formulations: physicochemical characterization and in vivo pharmacological studies

References

• Szejtli J. (1988). Cyclodextrin technology. Dordrecht: Kluwer Academic Publishers.
   Google Scholar
• Duchêne D. (1991). New trends in cyclodextrins and derivates. Paris: Edition de Santé.
   Google Scholar
• Loftsson T, Brewster ME. (1996). Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci, 85:1017–25.
   PubMed Web of Science ®Google Scholar
• Uekama K, Hirayama F, Irie T. (1998). Cyclodextrin drug carrier system. Chem Rev, 98:2045–76.
   PubMed Web of Science ®Google Scholar
• Brewster ME, Loftsson T. (2007). Cyclodextrins as pharmaceutical solubilizers. Adv Drug Del Rev, 59:645–66.
   PubMed Web of Science ®Google Scholar
• Rajewski RA, Stella VJ. (1996). Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J Pharm Sci, 85:1142–69.
   PubMed Web of Science ®Google Scholar
• Carrier RL, Miller LA, Ahmed I. (2007). The utility of cyclodextrins for enhancing oral bioavailability. J Control Release, 127:78–99.
   Web of Science ®Google Scholar
• Balfour JA, Buckley MMT. (1991). Etodolac—A reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states. Drugs, 42:274–99.
   PubMed Web of Science ®Google Scholar
• Reynolds JEF. (1996). Martindale, the extra pharmacopeia, 31st ed. London: Royal Pharmaceutical Society.
   Google Scholar
• Jones RA. (2001). Etodolac (Lodine): Profile of an established selective COX-2 inhibitor. Inflammopharmacology, 9:63–70.
   Google Scholar
• Glaser KA. (1995). Cyclooxygenase selectivity and NSAIDs: Cyclooxygenase-2 selectivity of etodolac (Lodine). Inflammopharmacology, 3:335–45.
   Google Scholar
• Inoue K, Fujisawa H, Motonaga A, Inoue Y, Kyoi T, Ueda F, . (1994). Anti-inflammatory effects of etodolac: Comparison with other non-steroidal anti-inflammatory drugs. Biol Pharm Bull, 17:1577–83.
   PubMed Web of Science ®Google Scholar
• Okamoto A, Shirakawa T, Bito T, Shigemura K, Hamada K, Gotoh A, . (2008). Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo. Urology, 71:156–60.
   PubMed Web of Science ®Google Scholar
• Nardella FA, LeFevre JA. (2002). Enhanced clearance of leukemic lymphocytes in B-cell chronic lymphocytic leukemia with Etodolac. Blood, 99:2625–6.
   PubMed Web of Science ®Google Scholar
• Remington. (2005). The Science and practice of pharmacy, 21st ed. Philadelphia: University of the Sciences in Philadelphia.
   Google Scholar
• Insel PA. (1996). Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In: Hardman JG, Goodman Gilman A, Limbird LE, eds. The pharmacological basis of therapeutics. New York: Mc Graw-Hill, 635.
   Google Scholar
• Milic-Askrabic J, Rajic DS, Tasic LJ, Djuric S, Kása P, Pintye-Hódi K. (1997). Etodolac and solid dispersion with β-cyclodextrin. Drug Dev Ind Pharm, 23:1123–9.
   Web of Science ®Google Scholar
• Cappello B, Iervolino M, La Rotonda MI, Miro A. (1999). Influence of different cyclodextrins of physicochemical and pharmacological properties of etodolac. Proceedings of the ninth international symposium on cyclodextrins. Santiago De Compostela (Spain), May 31–June 3, 467–70.
   Google Scholar
• Junco S, Cabral Marques HM. (2000). Complexation properties of etodolac and cyclodextrins prepared by different methods. Cyclodextrin: From basic research to market. 10th international cyclodextrin symposium. Ann Arbor (USA), May 21–24, 108–1113.
   Google Scholar
• Higuchi T, Connors KA. (1965). Phase-solubility techniques. Adv Anal Chem Instrum, 4:117–212.
   Google Scholar
• Blanco J, Vila-Jato JL, Otero FAS. (1991). Influence of method of preparation on inclusion complexes of naproxen with different cyclodextrins. Drug Dev Ind Pharm, 17:943–57.
   Web of Science ®Google Scholar
• Khan KA. (1975). The concept of dissolution efficiency. J Pharm Pharmacol, 27:48–9.
   PubMed Web of Science ®Google Scholar
• Inoue Y. (1993). NMR studies of the structural and the properties of cyclodextrins and their inclusion complexes. Annu Rep NMR Spectrosc, 27:59–101.
   Google Scholar
• Mucci A, Schenetti L, Vandelli MA, Ruozi B, Forni F. (1999). Evidence of the existence of 2:1 guest-host complexes between diclofenac and cyclodextrins in D2O solutions A1H and 13C NMR study on diclofenac/β-cyclodextrin and diclofenac/2-hydroxypropyl-β-cyclodextrin systems. J Chem Res Synop, 414:1761–95.
   Google Scholar
• Zhao D, Liao K, Ma X, Yan X. (2002). Study of the supramolecular inclusion of β-cyclodextrin with andrographolide. J Incl Phenom, 43:259–64.
   Web of Science ®Google Scholar
• Redenti E, Pasini M, Ventura P, Spisni A, Vikman M, Szejtli J. (1993). The terfenadine/β-cyclodextrin inclusion complex. J Incl Phenom, 15:281–92.
   Web of Science ®Google Scholar
• Liu C, Desai KGH, Liu C. (2005). Enhancement of dissolution rate of valdecoxib using solid dispersions with polyethylene glycol 4000. Drug Dev Ind Pharm, 31:1–10.
   PubMed Web of Science ®Google Scholar
• Barbato F, Cappello B, La Rotonda MI, Miro A, Quaglia F. (2003). Diclofenac/β-cyclodextrin binary system: A study in solution and in the solid state. J Incl Phenom, 46:179–85.
   Web of Science ®Google Scholar
• Mura P, Fauci MT, Parrini PL, Furlanetto S, Pinzauti S. (1999). Influence of the preparation method on the physicochemical properties of ketoprofen-cyclodextrin binary systems. Int J Pharm, 179:117–28.
   PubMed Web of Science ®Google Scholar
• Nakai Y, Yamamoto K, Terada K, Horibe H. (1984). Interaction of tri-O-methyl-β-cyclodextrin with drugs. J Incl Phenom, 2:523–31.
   Google Scholar
• Hatanaka H, Komada F, Mishima Y, Okumura K. (1993). Improved bioavailability of para-boronophenylalanine by cyclodextrin complexation. J Pharm Sci, 82:1054–7.
   PubMed Web of Science ®Google Scholar
• Chow DD, Karara AH. (1986). Characterization, dissolution and bioavailability in rats of ibuprofen-β-cyclodextrin complex system. Int J Pharm, 28:95–101.
   Web of Science ®Google Scholar
• Corrigan OI, Stanley T. (1982). Mechanism of drug dissolution rate enhancement from β-cyclodextrin-drug systems. J Pharm Pharmacol, 34:739–44.
   Google Scholar